Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
And just as there are over 200 medications for the treatment of type 2 diabetes or for the treatment of diabetes, there will be hundreds of medications for the treatment of obesity
Some researchers put the figure closer to 0.1% or less
Not everyone responds to tirzepatide
More is not always better with MOTS-c
2040 EORTC item Q168: the psychometric performance of a single-item indicator of side-effect burden for people with cancer Tamara Jones 1 , Florian Zeman 2 , Michael Koller 2 , Andreia Moura 3 , Claire Piccinin 3 , Sandra Nolte 1 1 Person-Centred Research, Eastern Health Clinical School, Monash University, Melbourne, Australia, 2 Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 3 Quality of Life Department, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :2040 Aims Following the release of the US Food and Drug Administration (FDA) Guidance on core patient-reported outcomes in cancer clinical trials, there has been growing interest in using single items to measure treatment tolerability from the patients perspective
